Blog
RSS FeedPosted by Michael Wonder on 17 Dec 2019
Report on the collection of under co-payment data 2018-19
17 December 2019 - The report on the collection of under co-payment data 2018-19 is now available. ...
Posted by Michael Wonder on 17 Dec 2019
Lamotrigine NPPA change
17 December 2019 - The request seeks all ‘communications’ between members of the PHARMAC senior leadership team, and in anticipation ...
Posted by Michael Wonder on 13 Dec 2019
Alberta changes coverage of biologic drugs for people with Crohn's, diabetes, arthritis
12 December 2019 - The provincial government says will free up hundreds of millions of dollars in health funding during the ...
Posted by Michael Wonder on 12 Dec 2019
Canadian study shows substantial savings possible with use of biosimilar filgrastim
12 December 2019 - During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar ...
Posted by Michael Wonder on 12 Dec 2019
Alberta will force patients to switch from biologics to cheaper biosimilar medications
12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...
Posted by Michael Wonder on 02 Dec 2019
Top 10 drugs 2018–19
2 December 2019 - Rosuvastatin calcium (Crestor) was the top PBS/RPBS drug by prescription counts. ...
Posted by Michael Wonder on 21 Nov 2019
Pricing tactics slow uptake of generic drugs by Medicare plans
21 November 2019 - Study finds new copycat medicines take years to win coverage. ...
Posted by Michael Wonder on 18 Nov 2019
Biosimilars make progress in the Canadian market, but stakeholders see more work ahead
18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its ...
Posted by Michael Wonder on 13 Nov 2019
Epilepsy NZ calls for halt to drug switch following deaths of three people
13 November 2019 - Epilepsy New Zealand is urging authorities to immediately halt a drug switch following the death of ...
Posted by Michael Wonder on 10 Oct 2019
Biosimilars in the UK: where are we now and where does the NHS want to go?
9 October 2019 - The UK health service has well over a decade’s experience of dealing with biosimilars, but the ...
Posted by Michael Wonder on 09 Oct 2019
Prescription opioid dispensing in Australian children and adolescents: a national population-based study
8 October 2019 - There are few population-based studies of paediatric opioid use. ...
Posted by Michael Wonder on 23 Sep 2019
Two more bills aiming to boost biosimilars introduced in Congress
23 September 2019 - Two biosimilar bills, both with bipartisan sponsors, were unveiled last week and aim to boost uptake in ...
Posted by Michael Wonder on 18 Sep 2019
Xanax still being overprescribed despite policy changes
19 September 2019 - Patients are still being prescribed hundreds of Xanax tablets a year despite a cut in government ...
Posted by Michael Wonder on 12 Sep 2019
Draft Pelosi plan targets drugs lacking biosimilar or generic option
12 September 2019 - While chances of her leaked plan to force lower drug prices in the United States getting through ...